A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma

M. L. Cloud, G. C. Enas, J. Kemp, T. Platts-Mills, L. C. Altman, R. Townley, D. Tinkelman, T. King, E. Middleton, A. L. Sheffer, E. R. McFadden, D. S. Farlow

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.

Original languageEnglish
Pages (from-to)1336-1339
Number of pages4
JournalAmerican Review of Respiratory Disease
Volume140
Issue number5
Publication statusPublished - 1989
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Cloud, M. L., Enas, G. C., Kemp, J., Platts-Mills, T., Altman, L. C., Townley, R., ... Farlow, D. S. (1989). A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. American Review of Respiratory Disease, 140(5), 1336-1339.